Sepulcre, J, Murie-Fernandez, M, Salinas-Alaman, A, Garcia-Layana, A, Bejarano, B, Villoslada, P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology May 1, 2007;68(18):1488–94.CrossRefGoogle ScholarPubMed

Green, AJ, McQuaid, S, Hauser, SL, Allen, IV, Lyness, R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain June 2010;133(Pt 6):1591–601.CrossRefGoogle ScholarPubMed

Engell, T. Neurological disease activity in multiple sclerosis patients with periphlebitis retinae. Acta Neurologica Scandinavica February 1986;73(2):168–72.Google ScholarPubMed

Herbort, CP, Rao, NA, Mochizuki, M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocular Immunology and Inflammation May–June 2009;17(3):160–9.CrossRefGoogle ScholarPubMed

Mili-Boussen, I, Letaief, I, Zbiba, W, Trabelsi, O, Ben Younes, N, Abid, J, et al. [Retinal vasculitis. Epidemiological, clinical and etiological features]. Journal Francais d’Ophtalmologie October 2010;33(8):529–37. Les vascularites retiniennes: profils epidemiologiques, cliniques et etiologiques.Google Scholar

Quillen, DA, Stathopoulos, NA, Blankenship, GW, Ferriss, JA. Lupus associated frosted branch periphlebitis and exudative maculopathy. Retina (Philadelphia, Pa) 1997;17(5):449–51.CrossRefGoogle ScholarPubMed

Rio, J, Colin, A, Salvador, F, Tintore, M, Viguera, ML, Montalban, J, et al. [Retinal periphlebitis in multiple sclerosis. A prospective study]. Neurologia (Barcelona, Spain). October 1993;8(8):252–5.Google ScholarPubMed

Tola, MR, Granieri, E, Casetta, I, Monari, P, Scorrano, R, Mazzeo, V, et al. Retinal periphlebitis in multiple sclerosis: a marker of disease activity? European Neurology 1993;33(2):93–6.CrossRefGoogle ScholarPubMed

Stamenkovic, M, Obradovic, D. Retinal periphlebitis in patients with multiple sclerosis. Vojnosanitetski Pregled Military – medical and pharmaceutical review July 2011;68(7):544–9.CrossRefGoogle ScholarPubMed

Schmidt, S, Wessels, L, Augustin, A, Klockgether, T. Patients with multiple sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. Journal of the Neurological Sciences June 15, 2001;187(1–2):49–53.CrossRefGoogle Scholar

Quentin, CD, Altenhoff, M, Schipper, HI, Vogel, M. [Retinal periphlebitis and multiple sclerosis. Incidence, cerebrospinal fluid and results of visual evoked potentials]. Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft 1990;87(4):359–61.Google ScholarPubMed

Barkhof, F, Calabresi, PA, Miller, DH, Reingold, SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nature reviews Neurology May 2009;5(5):256–66.CrossRefGoogle ScholarPubMed

Ortiz-Perez, S M-LE, Gabilondo, I, Fraga-Pumar, E, Martínez-Heras, E, Saiz, A, Sánchez-Dalmau, B, Villoslada P. Retinal periphlebitis is associated with multiple sclerosis severity. Neurology 2013;81(10):877–81.Google Scholar

Mackenzie, S, Schmermer, C, Charnley, A, Sim, D, Vikas, T, Dumskyj, M, et al. SDOCT imaging to identify macular pathology in patients diagnosed with diabetic maculopathy by a digital photographic retinal screening programme. PloS One 2011;6(5):e14811.CrossRefGoogle ScholarPubMed

Kappos, L, Radue, EW, O’Connor, P, Polman, C, Hohlfeld, R, Calabresi, P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. The New England Journal of Medicine. February 4, 2010;362(5):387–401.CrossRefGoogle ScholarPubMed

Malinowski, SM, Pulido, JS, Folk, JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology June 1993;100(6):818–24.CrossRefGoogle ScholarPubMed

Saidha, S, Sotirchos, ES, Ibrahim, MA, Crainiceanu, CM, Gelfand, JM, Sepah, YJ, et al. Microcystic macular edema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol November 2012;11(11):963–72.CrossRefGoogle ScholarPubMed

Gelfand, JM, Nolan, R, Schwartz, DM, Graves, J, Green, AJ. Microcystic macular edema in multiple sclerosis is associated with disease severity. Brain. June 2012;135(Pt 6):1786–93.CrossRefGoogle ScholarPubMed

Balk, LJ, Killestein, J, Polman, CH, Uitdehaag, BM, Petzold, A. Microcystic macular edema confirmed, but not specific for multiple sclerosis. Brain December 2012 Dec;135(Pt 12):e226; author reply e7.CrossRefGoogle Scholar

Sotirchos, ES, Saidha, S, Byraiah, G, Mealy, MA, Ibrahim, MA, Sepah, YJ, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology April 9, 2013 Apr 9;80(15):1406–14.CrossRefGoogle ScholarPubMed

Ikebe, T, Nakatsuka, K, Goto, M, Sakai, Y, Kageyama, S. A case of retinopathy induced by intravenous administration of interferon. Folia Ophthalmol Jpn (Ganka-Kiyo). 1990;41:6.Google Scholar

Fragoso, YD, Paggiaro, MS, Mastromauro, R, Jacondino Gda, S, Wilson, HM. Literature systematic review on the ophthalmological side effects of interferons. Arquivos Brasileiros de Oftalmologia. July–August 2011;74(4):306–10.CrossRefGoogle ScholarPubMed

Sommer, S, Sablon, JC, Zaoui, M, Rozot, P, Hosni, A. [Interferon beta-1 b retinopathy during a treatment for multiple sclerosis]. Journal Francais d’Ophtalmologie. May 2001;24(5):509–12.Google Scholar

Mallada-Frechin, J, Abellan-Miralles, I, Alfaro-Beltra, ML, Medrano, V, Munoz-Gil, MB, Fernandez-Izquierdo, S, et al. [Retinopathy secondary to treatment with Interferon beta-1a in a patient with multiple sclerosis]. Revista de Neurologia. April 16–30, 2005;40(8):482–4.Google Scholar

Hara, K, Tanito, M, Ohira, A. Retinal nerve fibre layer defects associated with cotton-wool spots in patients with interferon retinopathy. Acta Ophthalmologica. March 2012;90(2):e158–60.CrossRefGoogle ScholarPubMed

Ioannides, A, Georgakarakos, ND, Elaroud, I, Andreou, P. Isolated cotton-wool spots of unknown etiology: management and sequential spectral domain optical coherence tomography documentation. Clinical Ophthalmology (Auckland, NZ). 2011;5:1431–3.Google ScholarPubMed

Taylor, JL, Grossberg, SE. The effects of interferon-alpha on the production and action of other cytokines. Seminars in Oncology. Febrary 1998;25(1 Suppl 1):23–9.Google ScholarPubMed

Sugano, S, Suzuki, T, Watanabe, M, Ohe, K, Ishii, K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. The American Journal of Gastroenterology. December 1998;93(12):2441–4. PubMed PMID: 9860406. Epub 1998/12/22. eng.CrossRefGoogle ScholarPubMed

Lohmann, CP, Kroher, G, Bogenrieder, T, Spiegel, D, Preuner, J. Severe loss of vision during adjuvant interferon alfa-2 b treatment for malignant melanoma. Lancet. April 17, 1999;353(9161):1326.CrossRefGoogle ScholarPubMed

Guyer, DR, Tiedeman, J, Yannuzzi, LA, Slakter, JS, Parke, D, Kelley, J, et al. Interferon-associated retinopathy. Archives of Ophthalmology. March 1993;111(3):350–6.CrossRefGoogle ScholarPubMed